jak in 15

JAK-IN-15, a JAK inhibitor, is referenced in WO2016119700A1 (Compound 15).

1. Linderalactone showed significant inhibitory effects on superoxide anion generation by human neutrophils in response to fMLP CB, values of IC5 is 8.48 μg mL.

JAK-IN-23 is an orally active dual JAK STAT and NF-κB inhibitor that inhibits JAK1 (IC50: 8.9 nM), JAK2 (IC50: 15 nM), and JAK3 (IC50: 46.2 nM). It exhibits strong anti-inflammatory effects and can reduce the release of various pro-inflammatory factors. JAK-IN-23 can be used to study inflammatory bowel disease (IBD).

JAK-IN-24, a JAK inhibitor, exhibits IC50 values of 0.534 nM and 24 nM in the presence of 4 μM and 1 mM ATP, respectively. Additionally, it effectively inhibits STAT5 phosphorylation induced by PBMC IL-15 with an IC50 of 86.171 nM.

JAK-IN-30 (compound 31) is a water-soluble Janus kinase (JAK) inhibitor with IC50 values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2, identified for its research potential in treating dry eye disease (DED) [1].